Combined Biomarker System Predicts Prognosis in Patients with Metastatic Oral Squamous Cell Carcinoma

Cancers (Basel). 2023 Oct 10;15(20):4924. doi: 10.3390/cancers15204924.

Abstract

Background: Metastatic oral squamous cell carcinoma (OSCC) is associated with poor patient prognosis. Metastasis is a complex process involving various proteins, tumor cell alterations, including changes attributable to the epithelial-to-mesenchymal transition (EMT) process, and interactions with the tumor microenvironment (TME). In this study, we investigate a combined protein marker system consisting of connexin 43 (Cx43), EMMPRIN (CD147), E-cadherin, and vimentin, with a focus on their roles in the invasive metastatic progression of OSCC and their potential utility in predicting prognosis.

Methods: We conducted an immunohistochemical analysis to assess the protein expression profiles of Cx43, EMMPRIN, E-cadherin, and vimentin using tissue samples obtained from 24 OSCC patients. The metastatic process was mapped through different regions of interest (ROIs), including adjacent healthy oral mucosa (OM), center of primary OSCC, invasive front (IF), and local cervical lymph node metastases (LNM). The primary clinical endpoints were disease-free survival (DFS) and overall survival (OS).

Results: Substantial changes in the expression profiles of the different marker proteins were observed among the different ROIs, with all p-values < 0.05, signifying statistical significance. Multivariable Cox regression analysis results showed a significant effect of increased EMMPRIN expression toward the IF on DFS (p = 0.019) and OS (p = 0.023). Furthermore, the combined predictive analysis showed a significant predictive value of the marker system for DFS (p = 0.0017) and OS (p = 0.00044).

Conclusions: The combined marker system exhibited a significant ability to predict patient prognosis. An increase in EMMPRIN expression toward the IF showed the strongest effect and could be an interesting new antimetastatic therapy approach.

Keywords: E-cadherin; EMMPRIN; connexin 43; disease-free survival; epithelial-to-mesenchymal transition; metastasis; oral squamous cell carcinoma; overall survival; prognosis; vimentin.

Grants and funding

We acknowledge support from the Open Access Publication Funds/Transformative Agreements of the University of Goettingen. Michal Amit Rahat was funded by the Israel Science Foundation (ISF), grant number 2607/20.